These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 35027066)

  • 21. Association between the cardiometabolic index and non-alcoholic fatty liver disease: insights from a general population.
    Zou J; Xiong H; Zhang H; Hu C; Lu S; Zou Y
    BMC Gastroenterol; 2022 Jan; 22(1):20. PubMed ID: 35021995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is Vitamin D an Independent Risk Factor of Nonalcoholic Fatty Liver Disease?: a Cross-Sectional Study of the Healthy Population.
    Park D; Kwon H; Oh SW; Joh HK; Hwang SS; Park JH; Yun JM; Lee H; Chung GE; Ze S; Park JH; Bae Y; Lee A
    J Korean Med Sci; 2017 Jan; 32(1):95-101. PubMed ID: 27914137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of lipid accumulation product and its interaction with other factors on hypertension risk in Chinese Han population: A cross-sectional study.
    Song J; Zhao Y; Nie S; Chen X; Wu X; Mi J
    PLoS One; 2018; 13(6):e0198105. PubMed ID: 29874254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. External validation and comparison of simple tools to screen for nonalcoholic fatty liver disease in Chinese community population.
    Zhang L; Zhang M; Wang M; Wang M; Zhang R; Wang H; Zhang W; Ding Y; Wang J
    Eur J Gastroenterol Hepatol; 2022 Aug; 34(8):865-872. PubMed ID: 35802528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiometabolic index: a new tool for screening the metabolically obese normal weight phenotype.
    Liu X; Wu Q; Yan G; Duan J; Chen Z; Yang P; Bragazzi NL; Lu Y; Yuan H
    J Endocrinol Invest; 2021 Jun; 44(6):1253-1261. PubMed ID: 32909175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of non-invasive indicators in the screening of metabolic dysfunction-associated fatty liver disease: a cross-sectional study among Uighurs in rural Xinjiang.
    Guo Y; Hu Y; Yang J; Ma R; Zhang X; Guo H; Wang X; Li Y; Peng X; Zhang S; He J; Guo S
    Eur J Med Res; 2023 Dec; 28(1):555. PubMed ID: 38042816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction of lipid accumulation product and family history of hypertension on hypertension risk: a cross-sectional study in the Southern Chinese population.
    Huang J; Bao X; Xie Y; Zhang X; Peng X; Liu Y; Cheng M; Ma J; Wang P
    BMJ Open; 2019 Nov; 9(11):e029253. PubMed ID: 31784431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between cardiometabolic index and controlled attenuation parameter in U.S. adults with NAFLD: findings from NHANES (2017-2020).
    Xi WF; Yang AM
    Lipids Health Dis; 2024 Feb; 23(1):40. PubMed ID: 38326824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Visceral Adiposity Surrogates with Impaired Fasting Glucose in Nonobese Individuals.
    Li HH; Wang JM; Ji YX; Lin L; Li SW; Cai D; Huang S; Hua F; Liu XZ
    Metab Syndr Relat Disord; 2020 Apr; 18(3):128-133. PubMed ID: 31999502
    [No Abstract]   [Full Text] [Related]  

  • 30. Association of epicardial fat volume and nonalcoholic fatty liver disease with metabolic syndrome: From the CAESAR study.
    Kim BJ; Kim HS; Kang JG; Kim BS; Kang JH
    J Clin Lipidol; 2016; 10(6):1423-1430.e1. PubMed ID: 27919360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gender impacts on the correlations between nonalcoholic fatty liver disease and hypertension in a Chinese population aged 45-60 y.
    Li XD; Qiu BH; Su FC; Sun SX
    Clin Exp Hypertens; 2016; 38(7):639-643. PubMed ID: 27680771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of Fatty Liver Index and Metabolic Factors in the Prediction of Nonalcoholic Fatty Liver Disease in a Lean Population Receiving Health Checkup.
    Hsu CL; Wu FZ; Lin KH; Chen YH; Wu PC; Chen YH; Chen CS; Wang WH; Mar GY; Yu HC
    Clin Transl Gastroenterol; 2019 May; 10(5):1-8. PubMed ID: 31082856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Different Anthropometric Indicators for Screening for Nonalcoholic Fatty Liver Disease in Elderly Individuals.
    Zhang Y; Li B; Liu N; Wang P; He J
    Int J Endocrinol; 2021; 2021():6678755. PubMed ID: 33574841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The usefulness of obesity and lipid-related indices to predict the presence of Non-alcoholic fatty liver disease.
    Sheng G; Lu S; Xie Q; Peng N; Kuang M; Zou Y
    Lipids Health Dis; 2021 Oct; 20(1):134. PubMed ID: 34629059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipid accumulation product is a reliable indicator for identifying metabolic syndrome: the China Multi-Ethnic Cohort (CMEC) Study.
    Zhang X; Hong F; Liu L; Nie F; Du L; Guan H; Wang Z; Zeng Q; Yang J; Wang J; Li X; Zhang J; Luo P
    QJM; 2022 Mar; 115(3):140-147. PubMed ID: 33367838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Visceral fat area to appendicular muscle mass ratio as a predictor for nonalcoholic fatty liver disease independent of obesity.
    Shi YX; Chen XY; Qiu HN; Jiang WR; Zhang MY; Huang YP; Ji YP; Zhang S; Li CJ; Lin JN
    Scand J Gastroenterol; 2021 Mar; 56(3):312-320. PubMed ID: 33535004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined Association of Vitamin D and Sex Hormone Binding Globulin With Nonalcoholic Fatty Liver Disease in Men and Postmenopausal Women: A Cross-Sectional Study.
    Wang N; Zhai H; Zhu C; Li Q; Han B; Chen Y; Zhu C; Chen Y; Xia F; Lin D; Lu Y
    Medicine (Baltimore); 2016 Jan; 95(4):e2621. PubMed ID: 26825918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of lipid accumulation product with chronic kidney disease in Chinese community adults: a report from the REACTION study.
    Yan P; Xu Y; Miao Y; Tang Q; Wu Y; Bai X; Zhang Z; Li Q; Wan Q
    Lipids Health Dis; 2021 Oct; 20(1):131. PubMed ID: 34627270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-invasive diagnosis of non-alcoholic fatty liver disease using an algorithm combining clinical indexes and ultrasonographic measures.
    Preciado-Puga MC; Ruiz-Noa Y; Garcia-Ramirez JR; Jordan-Perez B; Garnelo-Cabañas S; Lazo de la Vega-Monroy ML; Gutierrez-Aguirre KI; Ibarra-Reynoso LR
    Ann Hepatol; 2021; 21():100264. PubMed ID: 33031969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease.
    Zhang S; Du T; Zhang J; Lu H; Lin X; Xie J; Yang Y; Yu X
    Lipids Health Dis; 2017 Jan; 16(1):15. PubMed ID: 28103934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.